

SUPPLEMENTARY INFORMATION

Bioactive poly(2-oxazoline)-based nanomaterials bearing arylalkylamine and benzamide motifs possess intrinsic radical trapping and anti-ferroptosis properties

Joshua P. Morrow,[†] David Pizzi,[†] Zihnil A. I. Mazrad,[†] Ashley I. Bush,[±] and Kristian Kempe^{‡}*

[†] Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

[±] Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3052, Australia

[‡] Materials Science and Engineering, Monash University, Clayton, VIC 3800, Australia;

Corresponding author e-mail: kristian.kempe@monash.edu

Table of contents:

- I. Abbreviations
- II. Additional characterization by ^1H NMR spectroscopy and SEC chromatography of M45F4R and associated polymers
- III. Additional characterization of the P(MeOx-grad-PhOx) library by ^1H NMR spectroscopy, DLS, SEC chromatography and their cytocompatibility in N27 cells
- IV. Descriptions of polymer EC_{50} values
- V. Validation of compatible treatment conditions for flow cytometry
- VI. Additional characterization of CCMs by ^1H NMR spectroscopy, DLS and SEC chromatography
- VII. Supplementary confocal and flow cytometry investigations for evaluating therapeutic nanomaterials

Abbreviations

ROS reactive oxygen species
GPX4 glutathione peroxidase 4
DMT1 Divalent metal transporter 1
ACSL3/4 acyl-CoA synthetase long chain family member 3 and 4
ALOX Arachidonate lipoxygenase
AD Alzheimer's disease
Fer-1 ferrostatin-1
Lip-1 lipoxstatin-1
Cy5 cyanine 5
RTA radical trapping antioxidants
BBB blood brain barrier
POx-poly(oxazoline)s
PDCs polymer drug conjugates
PD pharmacodynamics
MeOx-2-methyl-2-oxazoline
PhOx 2-phenyl-2-oxazoline
DPhOx 2-(4-(1,3-dioxolan-2-yl)phenyl)-2-oxazoline
AldOx aldehyde functional deprotected-2-(4-(1,3-dioxolan-2-yl)phenyl)-2-oxazoline
BuOx 2-butyl-2-oxazoline
CCMs core crosslinked micelles
CMC critical micelle concentration
SAR structure activity relationship
C₁₁-BODIPY membrane sensor for lipid peroxidation
BODIPY-(488/530) oxidized membrane sensor for lipid peroxidation

Polymer library

M45F4R MeOx45Ferrostatin4 reduced
M45D4 MeOx45Diarylamine4
M45P5 MeOx45PhOx5
M20P40 MeOx20PhOx40
M30P20 MeOx30PhOx20
M40P10 MeOx40PhOx10
M30P15Ald5 MeOx30PhOx15AldOx5
M30P15D4 MeOx30PhOx15Diarylamine5
M36B23 MeOx36BuOx23
Et-CCM ethylenediamine crosslinked core crosslinked micelles
Ph-CCM p-phenylenediamine crosslinked core crosslinked micelles

Table S1. Further characterization of DPhOx based copolymers and related nanomaterials.

Polymer	DP (MeOx)	DP (co-monomer)	Pre-modification		Đ
			M _n , NMR (g mol ⁻¹)	M _n , SEC (g mol ⁻¹)	
M45F4R	45	4	5606	12500	1.21
M45D4	45	4	4861	10600	1.14
M45P5	45	5	4598	9300	1.14

Table S2. EC₅₀ values for bioactive polymers in this study

Polymer	EC ₅₀ (mM)
M45P5	1.32
M45D4	0.13
M45F4R	0.66 x 10 ⁻³
M40P10	0.25
M30P20	0.11
M30P15D5	0.052
M20P40	0.03
Ph-CCM	0.008
Et-CCM	0.024




Figure S1. ^1H NMR spectra of the PhOx containing polymers at different stages of synthesis.




Figure S2. N-Benzylaniline (NBA) suppresses ferroptosis at concentration equal to number of polymeric units of arylalkylamine.




Figure S3. Characterization of P(MeOx-grad-PhOx) library. A) ^1H NMR spectra of copolymers with increasing % benzamide content and B) their resulting SEC chromatograms. C) AlamarBlue cell viability assay in N27 cells of M30P20 after 24 hours with up to 5.0 mg mL^{-1} polymer.




Figure S4. DLS study showing normalized % intensity traces of P(MeOx-grad-PhOx) library and Ph-CCM_{cy5}.




Figure S5. % Viable cells determined by PI for treatment conditions used in flow cytometry experiments with C₁₁-BODIPY. A) P(MeOx-grad-PhOx) library and M30P15D5. B) CCMs and series. C) Controls for C₁₁-BODIPY probe showing average ROS activated BODIPY- (488/530) MFI of cell populations (red-no treatment, light green-H₂O₂ 500 μ M, blue-RSL3 1 μ M, orange-RSL3+Fer-1 1 μ M, blue-RSL3+M36B23 1 mg mL⁻¹).




Figure S6. ¹H NMR spectra of linear polymer arm containing AldOx (M30P15Ald5), its modification with Cy5 (M30P15D5-Cy5), aniline (M30P15D5) and then Ph-CCM_{cy5}.




Figure S7. DLS of CCMs in different solvents (left: Ph-CCM, right: Et-CCM). M30P20 “arm” was attempted in DMF but did not self-assemble in this solvent. Concentration used for all samples – 1 mg mL^{-1} .




Figure S8. Dose-response curves of M30P20 and Ph-CCM plotted against mg mL^{-1} highlighting comparison of relatively similar % benzamide content and response to ferroptosis and additionally the lack of effect of CMC on ferroptosis suppression.




Figure S9. Bright field images from C_{11} -BODIPY confocal experiment highlighting cell appearance (black arrows: healthy cells with neurite outgrowth, orange: unhealthy constricted cells). RSL3 – 1 μ M, polymer – 1 mg mL^{-1} .




Figure S10. Fluorescent images from C_{11} -BODIPY experiment showing the M36B23 control producing ROS-activated BODIPY-(488/530) from membrane lipid peroxidation. RSL3 – 1 μ M, polymer – 1 mg mL^{-1} .




Figure S11. Ph-CCM_{Cy5} characterization by SEC chromatography (Normalized UV absorbance at 646 nm).




Figure S12. Lysosomal colocalization experiment in RSL3 treated cells (RSL3 at 1 μM for 4 hours as cotreatment). Arm-M30P15D_{5_{Cy5}}, CCM-Ph-CCM_{Cy5}. Green channel-lysotrackerGreen, red channel- polymer Cy5, grey channel-colocalization using “AND” function in FIJI image calculator. Scale bar 20 μm .




Figure S13. Bioactive polymers attenuate alternate models of ferroptosis in N27 and SH-SY5Y.